<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Source Themes Academic 4.8.0">

  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="DrugBank ID: db00811 DrugCentral: ribavirin Synonymous :1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide | 1-beta-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide | rbv | ribavirin | ribavirina | ribavirine | ribavirinum | tribavirin 
Drug Sentece Context Table 1. Analysis of context sentence of ribavirin gene in 167 abstracts.">

  
  <link rel="alternate" hreflang="en-us" href="https://platcovid.com/drugpanel/ribavirin/info/">

  


  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css" integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js" integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    

  

  
  
  
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
  

  
  
  
  
  <link rel="stylesheet" href="/css/academic.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=UA-166873339-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'UA-166873339-1', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu7e12209333f22d741aca7d462871821f_9877_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="https://platcovid.com/drugpanel/ribavirin/info/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="PlatCOVID">
  <meta property="og:url" content="https://platcovid.com/drugpanel/ribavirin/info/">
  <meta property="og:title" content="RIBAVIRIN | PlatCOVID">
  <meta property="og:description" content="DrugBank ID: db00811 DrugCentral: ribavirin Synonymous :1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide | 1-beta-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide | rbv | ribavirin | ribavirina | ribavirine | ribavirinum | tribavirin 
Drug Sentece Context Table 1. Analysis of context sentence of ribavirin gene in 167 abstracts."><meta property="og:image" content="https://platcovid.com/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="https://platcovid.com/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2019-05-05T00:00:00&#43;01:00">
    
    <meta property="article:modified_time" content="2019-05-05T00:00:00&#43;01:00">
  

  



  


  


  





  <title>RIBAVIRIN | PlatCOVID</title>

</head>

<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" >

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  







<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">PlatCOVID</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax/"><span>Syntax</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/genepanel/"><span>Gene Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link  active" href="/drugpanel/"><span>Drug Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/tissuepanel/"><span>Tissue Panel</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        

        <li class="nav-item">
          <a class="nav-link " href="/syntax_summary/"><span>Literature Consensus</span></a>
        </li>

        
        

        

        
        
        
          
        

        
        
        
        
        
        
          
          
          
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#about"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      

      

    </ul>

  </div>
</nav>


  <article class="article">

  












  

  
  
  
<div class="article-container pt-3">
  <p style="font-size:25px" align="justify">RIBAVIRIN</p>

  

  
    


<div class="article-metadata">

  
  

  

  

  

  
  
  

  
  

</div>

    














  
</div>



  <div class="article-container">

    <div class="article-style">
      
<script src="/rmarkdown-libs/header-attrs/header-attrs.js"></script>
<script src="/rmarkdown-libs/kePrint/kePrint.js"></script>
<link href="/rmarkdown-libs/lightable/lightable.css" rel="stylesheet" />


<hr />
<p align="left" style="font-size:16px">
DrugBank ID: <a href='https://www.drugbank.ca/drugs/db00811' target='_blank'>db00811</a> <br>
DrugCentral: <a href="http://drugcentral.org/?q=ribavirin" target="_blank">ribavirin</a> <br>
Synonymous :1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide | 1-beta-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide | rbv | ribavirin | ribavirina | ribavirine | ribavirinum | tribavirin
</p>
<p><br></p>
<hr />
<div id="drug-sentece-context" class="section level2">
<h2>Drug Sentece Context</h2>
<br>
<p style="font-size:12px" align="center">
<strong>Table 1.</strong> Analysis of context sentence of <em>ribavirin</em> gene in 167 abstracts.
</p>
<table class="table table-striped" style="width: auto !important; margin-left: auto; margin-right: auto;">
<thead>
<tr>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
pmid
</th>
<th style="text-align:center;position: sticky; top:0; background-color: #FFFFFF;">
sentence
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32023685" target="_blank">32023685</a>
</td>
<td style="text-align:center;">
Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32057209" target="_blank">32057209</a>
</td>
<td style="text-align:center;">
Combination of Ribavirin and Interferon-α is recommended by the 5(th) edition National Health Commission’s Regimen (Revised Edition) because of the effect on MERS (Middle East Respiratory Syndrome), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32119961" target="_blank">32119961</a>
</td>
<td style="text-align:center;">
Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. […] The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32164080" target="_blank">32164080</a>
</td>
<td style="text-align:center;">
Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32164081" target="_blank">32164081</a>
</td>
<td style="text-align:center;">
Combination of Ribavirin and interferon-α is recommended by the 5(th) edition National Health Commission’s Regimen (Revised Edition) because of the effect on Middle East respiratory syndrome (MERS), and the effectiveness of Lopinavir/Ritonavir and Remdisivir needs to be confirmed by randomized controlled trial (RCT), given the situation of no specific antivirus drug on NCP is unavailable.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32164424" target="_blank">32164424</a>
</td>
<td style="text-align:center;">
Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32179150" target="_blank">32179150</a>
</td>
<td style="text-align:center;">
Chloroquine, remdesivir, lopinavir, ribavirin and ritonavir have shown efficacy to inhibit coronavirus in vitro.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32218301" target="_blank">32218301</a>
</td>
<td style="text-align:center;">
These molecules proved to be the most effective antiviral agents, able to reach the potency profile of the licensed drug ribavirin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32219882" target="_blank">32219882</a>
</td>
<td style="text-align:center;">
To help understand the advantages and limitations of differential treatments, we provide a timely review and discuss the complications and corresponding major treatments, especially controversial ones such as antiviral therapy (remdesivir, ribavirin, and chloroquine), glucocorticoid therapy, extracorporeal support including an artificial liver system, and extracorporeal membrane oxygenation based on available evidence.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32222463" target="_blank">32222463</a>
</td>
<td style="text-align:center;">
The results suggest the effectiveness of Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir as potent drugs against SARS-CoV-2 since they tightly bind to its RdRp.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32227274" target="_blank">32227274</a>
</td>
<td style="text-align:center;">
Furthermore, COVID-19 mRNA clearance time was positively correlated with the length of hospital stay in patients treated with either IFN-α + lopinavir/ritonavir or IFN-α + lopinavir/ritonavir + ribavirin. […] Therapeutic regimens of IFN-α + lopinavir/ritonavir and IFN-α + lopinavir/ritonavir + ribavirin might be beneficial for treatment of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32227493" target="_blank">32227493</a>
</td>
<td style="text-align:center;">
The access to direct antiviral drugs, such as ribavirin, that have an existing inventory and reliable supply chain may be a priority consideration for therapies developed for the 2019-nCoV infection outbreaks and any strain variants that may emerge. […] On the basis of the direct antiviral activity of ribavirin against 2019-nCoV in vitro and evidence for potency enhancement strategies developed during the prior SARS and MERS outbreaks, ribavirin may significantly impact our ability to end the lingering outbreaks in China and slow outbreaks in other countries. […] The apparent COVID-19 pandemic provides an opportunity to follow dosage guidelines for treatment with ribavirin, test new therapeutic concepts, and conduct controlled testing to apply the scientific rigor required to address the controversy around this mainstay of antiviral therapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243270" target="_blank">32243270</a>
</td>
<td style="text-align:center;">
This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab and sarilumab.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32246834" target="_blank">32246834</a>
</td>
<td style="text-align:center;">
In addition to the recommended antiviral drugs such as interferon-ɑ, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA dependent RNA polymerase (RdRp) inhibitors have been registered and initiated.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32251634" target="_blank">32251634</a>
</td>
<td style="text-align:center;">
The top 20 drugs in the virtual screening studies comprised a broad-spectrum antiviral (ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other miscellaneous systemically acting drugs. […] Of special interest, ribavirin had been used in treating cases of SARS CoV. […] Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32251767" target="_blank">32251767</a>
</td>
<td style="text-align:center;">
Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 μM.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32284326" target="_blank">32284326</a>
</td>
<td style="text-align:center;">
In this regard, the triphosphate forms of 2’-C-methylated compounds, including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32307245" target="_blank">32307245</a>
</td>
<td style="text-align:center;">
However, the regimen of LPV/RTV plus ribavirin was shown to be effective against SARS-CoV in vitro.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32338164" target="_blank">32338164</a>
</td>
<td style="text-align:center;">
The results show the effectiveness of Sofosbuvir, Ribavirin, Galidesivir, Remdesivir, Favipiravir, Cefuroxime, Tenofovir, and Hydroxychloroquine, in binding to SARS-CoV-2 RdRp.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32352535" target="_blank">32352535</a>
</td>
<td style="text-align:center;">
Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32354369" target="_blank">32354369</a>
</td>
<td style="text-align:center;">
The patient received combination of interferonalfa-1b and ribavirin, lopinavir and ritonavir for antiviral treatment at different stages.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32360583" target="_blank">32360583</a>
</td>
<td style="text-align:center;">
We searched PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and WANFANG DATA for randomized controlled trials (RCTs), prospective cohort, and retrospective cohort studies that evaluated therapies (hydroxychloroquine, lopinavir/ritonavir-based therapy, and ribavirin-based therapy, etc.) for SARS, MERS, and COVID-19. […] Subgroup analyses demonstrated that the combination of ribavirin and corticosteroids remarkably decreased mortality (RR 0.43, 95% CI 0.27-0.68). […] For safety, ribavirin could induce more bradycardia, anemia and transaminitis. […] Conversely, ribavirin might cause more safety concerns especially bradycardia.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32363963" target="_blank">32363963</a>
</td>
<td style="text-align:center;">
This is a report of a case with mucous membrane pemphigoid (MMP) with severe eye involvement and concurrent COVID-19 treated successfully using simultaneous high dose intravenous immunoglobulin (IVIg) and anti-viral treatment as hydroxychloroquine, lopinavir/ritonavir, and ribavirin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32375574" target="_blank">32375574</a>
</td>
<td style="text-align:center;">
This study demonstrated the putative inhibitory potential of lopinavir, remdesivir, oseltamir, azithromycin, ribavirin, and chloroquine towards V-ATPase, protein kinase A, SARS-CoV spike glycoprotein/ACE-2 complex and viral proteases. […] Moreover, it was also observed that chloroquine has appreciable binding affinities for 3-Chymotrpsin- like protease and cyclic AMP-dependent protein kinase A when compared to Oseltamivir and ribavirin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32389723" target="_blank">32389723</a>
</td>
<td style="text-align:center;">
Ribavirin, a common antiviral drug, remdesivir, chloroquine and luteolin were studied.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32391234" target="_blank">32391234</a>
</td>
<td style="text-align:center;">
He positively responded to a 14-day course of Lopinavir-Ritonavir, Ribavirin, Azithromycin, and Hydroxychloroquine.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32394467" target="_blank">32394467</a>
</td>
<td style="text-align:center;">
Ribavirin reduces hemoglobin concentrations in respiratory patients, and remdesivir improves respiratory symptoms. […] Use of ribavirin in combination with LPV/r in patients with SARS-CoV reduces acute respiratory distress syndrome and mortality, which has a significant protective effect with the addition of corticosteroids.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32401715" target="_blank">32401715</a>
</td>
<td style="text-align:center;">
We assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID-19. […] Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32404786" target="_blank">32404786</a>
</td>
<td style="text-align:center;">
All patients were treated with interferon, 6 cases combined with Ribavirin, and 12 cases combined with lopinavir or ritonavir. […] There was no significant difference of RNA turning negative between the groups of interferon, interferon plus ribavirin and interferon plus lopinavir or ritonavir treatment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32405454" target="_blank">32405454</a>
</td>
<td style="text-align:center;">
Lopinavir/ritonavir (200mg/50mg) two tablet tow times, Ribavirin 200mg every six hours, and Oseltamivir 75mg tow times were given for the treatment of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32446167" target="_blank">32446167</a>
</td>
<td style="text-align:center;">
All patients have received interferon-α nebulization, and eight cases including the severe and critical cases were co-administrated ribavirin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32458149" target="_blank">32458149</a>
</td>
<td style="text-align:center;">
A number of anti-viral drugs such as ribavirin, remdesivir, lopinavir/ritonavir, antibiotics such as azithromycin and doxycycline, and anti-parasite such as ivermectin have been recommended for COVID-19 treatment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32486229" target="_blank">32486229</a>
</td>
<td style="text-align:center;">
In this study, the bioactivity of some selected heterocyclic drugs named Favipiravir (<b>1</b>), Amodiaquine (<b>2</b>), 2’-Fluoro-2’-deoxycytidine (<b>3</b>), and Ribavirin (<b>4</b>) was evaluated as inhibitors and nucleotide analogues for COVID-19 using computational modeling strategies.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32493740" target="_blank">32493740</a>
</td>
<td style="text-align:center;">
We included studies of ribavirin, chloroquine, hydroxychloroquine, umifenovir (arbidol), favipravir, interferon and lopinavir/ritonavir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32496210" target="_blank">32496210</a>
</td>
<td style="text-align:center;">
A dual-combination of ribavirin and interferon-α has been the widely used regimen for the treatment of this disease in China.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32496357" target="_blank">32496357</a>
</td>
<td style="text-align:center;">
Ten received toclizumab and/or ribavirin; 1 received remdesivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32512873" target="_blank">32512873</a>
</td>
<td style="text-align:center;">
This strategy has been implemented for other respiratory viruses (influenza above all) and was successfully used in South Korea among healthcare workers against the Middle East respiratory syndrome (MERS) coronavirus, by providing people who were exposed to high-risk contacts with lopinavir-ritonavir plus ribavirin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32514228" target="_blank">32514228</a>
</td>
<td style="text-align:center;">
Certain drugs that are clinically approved for other diseases were tested against COVID-19 as chloroquine, hydroxychloroquine, ivermectin, favipiravir, ribavirin, and remdesivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32515383" target="_blank">32515383</a>
</td>
<td style="text-align:center;">
Lopinavir/Ritonavir, Ribavirin, remdesivir and Ravipiravir are some of the major antiviral agents showing initial encouraging results.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32520888" target="_blank">32520888</a>
</td>
<td style="text-align:center;">
All patients were treated with interferon, 6 cases combined with Ribavirin, and 12 cases combined with lopinavir or ritonavir. […] There was no significant difference of RNA turning negative between the groups of interferon, interferon plus ribavirin and interferon plus lopinavir or ritonavir treatment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32527340" target="_blank">32527340</a>
</td>
<td style="text-align:center;">
The main antiviral drugs included α-interferon (69.5%), lopinavir/ritonavir (65.0%), abidol (60.0%), and ribavirin (55.7%).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32532939" target="_blank">32532939</a>
</td>
<td style="text-align:center;">
Hydroxychloroquine, lopinavir/ritonavir, remdesivir, umifenovir, favipiravir, ribavirin and beta-interferon-1 gave rise to variable but still inconsistent proof of clinical efficacy in the treatment of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32546018" target="_blank">32546018</a>
</td>
<td style="text-align:center;">
However, the present review aims to highlight the important antiviral approaches, including interferons, ribavirin, mycophenolic acids, ritonavir, lopinavir, inhibitors, and monoclonal antibodies (mAbs) to provoke the nonstructural proteins and deactivate the structural and essential host elements of the virus to control and treat the infection of COVID-19 by inhibiting the viral entry, viral RNA replication and suppressing the viral protein expression. […] Different antivirals, including interferons, ribavirin, lopinavir, and monoclonal antibodies (mAbs) could be the potent therapeutic agents against COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32554953" target="_blank">32554953</a>
</td>
<td style="text-align:center;">
Several anti-viral drugs such as RNA dependent RNA polymerase inhibitors (remdesivir, favipiravir, ribavirin), protease inhibitors (lopinavir, ritonavir) and drugs targeting endocytic pathway (hydroxychloroquine) are being evaluated for COVID-19 but standard therapeutics yet not available.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32565309" target="_blank">32565309</a>
</td>
<td style="text-align:center;">
Our results for the first time suggest that a quadruple combination therapy (Ribavirin, Lopinavir/ritonavir, Umifenovir, and Lianhua Qingwen) can be considered as a preferred treatment approach to severe COVID-19 patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32566561" target="_blank">32566561</a>
</td>
<td style="text-align:center;">
For adults with SARS, interferon was associated with reduced corticosteroid dose [weighted mean difference (WMD) = -0.14 g; 95% CI, -0.21 to -0.07] but had no effect on mortality (RR =0.72; 95% CI, 0.28 to 1.88); ribavirin did not reduce mortality (RR =0.68; 95% CI, 0.43 to 1.06) and was associated with high risk of severe adverse reactions; and oseltamivir had no effect on mortality (RR =0.87; 95% CI, 0.55 to 1.38). […] Ribavirin combined with interferon was also not effective in adults with MERS and associated with adverse reactions.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32612432" target="_blank">32612432</a>
</td>
<td style="text-align:center;">
As ribavirin and favipiravir have teratogenic effects, there are some debates on the use of ribavirin in severe cases.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32612804" target="_blank">32612804</a>
</td>
<td style="text-align:center;">
A preliminary search identified the following drugs as being used to treat COVID-19 symptoms: atazanavir (ATV), azithromycin (AZI), chloroquine (CLQ)/hydroxychloroquine (HCLQ), dipyridamole, famotidine (FAM), favipiravir, lopinavir/ritonavir (LPV/r), nitazoxanide, remdesivir, ribavirin and tocilizumab.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32631826" target="_blank">32631826</a>
</td>
<td style="text-align:center;">
These repurposed drugs have mainly included remdesivir, favipiravir, lopinavir-ritonavir, ribavirin, interferons, and hydroxychloroquine.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32634080" target="_blank">32634080</a>
</td>
<td style="text-align:center;">
Several compounds, including remdesivir, lopinavir, ritonavir, interferon-β, ribavirin, chloroquine/hydroxychloroquine, azithromycin, tocilizumab, and ivermectin, have emerged as promising alternatives.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32634603" target="_blank">32634603</a>
</td>
<td style="text-align:center;">
Ribavirin may be beneficial as an add-on therapy but is ineffective as monotherapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32641471" target="_blank">32641471</a>
</td>
<td style="text-align:center;">
Use of lopinavir-ritonavir ±ribavirin + interferon beta (aOR 1.94, 95% CI 1.20 to 3.13, p=0.006) and corticosteroids (aOR 3.92, 95% CI 2.14 to 7.16, p&lt;0.001) was independently associated with ALT/AST elevation. […] Use of lopinavir-ritonavir, with or without ribavirin, interferon beta and/or corticosteroids was independently associated with ALT/AST elevation.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32655019" target="_blank">32655019</a>
</td>
<td style="text-align:center;">
Oseltamivir and ribavirin require dose modification in patients with moderate to severe CKD.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32659126" target="_blank">32659126</a>
</td>
<td style="text-align:center;">
Dose modification/avoidance should be considered for chloroquine, atazanavir, oseltamivir, ribavirin, anakinra, and Janus associated kinase inhibitors in patients with organ function impairment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32667665" target="_blank">32667665</a>
</td>
<td style="text-align:center;">
Furthermore, we implemented a coexpression drug repositioning analysis, cogena, and identified two antiviral drugs (saquinavir and ribavirin) and several other candidate drugs (such as dinoprost, dipivefrine, dexamethasone and (-)-isoprenaline). […] Notably, the two antiviral drugs have also previously been identified using molecular docking methods, and ribavirin is a recommended drug in the diagnosis and treatment protocol for COVID pneumonia (trial version 5-7) published by the National Health Commission of the P.R. of China.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32678017" target="_blank">32678017</a>
</td>
<td style="text-align:center;">
In the cases we report, the patient continued to deteriorate even after administration of antiviral drugs such as lopinavir/ritonavir, interferon-α, and ribavirin, as well as intravenous injection of meropenem, methylprednisolone, and immunoglobulin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32682788" target="_blank">32682788</a>
</td>
<td style="text-align:center;">
Several drugs such as Remdesivir, Hydroxychloroquine, Chloroquine, Ribavirin, Ritonavir, Lopinavir, Favipiravir, Interferons, Bevacizumab, Azithromycin, etc. are currently under clinical trials.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32685234" target="_blank">32685234</a>
</td>
<td style="text-align:center;">
Currently, the management of patients with COVID-19 depends mainly on repurposed drugs which include chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, remdesivir, favipiravir, umifenovir, interferon-α, interferon-β and others.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32694915" target="_blank">32694915</a>
</td>
<td style="text-align:center;">
Hydroxychloroquine/chloroquine, lopinavir/ritonavir, ribavirin, interferons, umifenovir, remdesivir, and interleukin antagonists, such as tocilizumab, have been recommended as potential treatment options in COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32711596" target="_blank">32711596</a>
</td>
<td style="text-align:center;">
We started a study on the molecular docking of six potential pharmacologically active inhibitors compounds that can be used clinically against the COVID-19 virus, in this case, remdesivir, ribavirin, favipiravir, galidesivir, hydroxychloroquine and chloroquine interacting with the main COVID-19 protease in complex with a COVID-19 N3 protease inhibitor. […] The highest values of affinity energy found in order from highest to lowest were chloroquine (CHL), hydroxychloroquine (HYC), favipiravir (FAV), galidesivir (GAL), remdesivir (REM) and ribavirin (RIB).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32712334" target="_blank">32712334</a>
</td>
<td style="text-align:center;">
The aim of this study was to compare ribavirin therapy versus supportive therapy only for patients with severe coronavirus disease 2019 (COVID-19). […] The 115 patients comprised 44 patients who received intravenous ribavirin (treatment group) and 71 who did not (control group). […] The negative conversion time for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR in the ribavirin group was 12.8 ± 4.1 days compared with 14.1 ± 3.5 days in the control group (P = 0.314). […] Moreover, 7/41 patients (17.1%) in the ribavirin group died compared with 17/69 (24.6%) in the control group (P = 0.475). […] In conclusion, in patients with severe COVID-19, ribavirin therapy is not associated with improved negative conversion time for SARS-CoV-2 test and is not associated with an improved mortality rate.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32717568" target="_blank">32717568</a>
</td>
<td style="text-align:center;">
Chloroquine, remdesivir, lopinavir/ritonavir or ribavirin have all been successful in inhibiting SARS-CoV-2 in vitro.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32725382" target="_blank">32725382</a>
</td>
<td style="text-align:center;">
We found promising in vitro evidence for remdesivir, (hydroxy)chloroquine and favipiravir against SARS-CoV-2; potential clinical benefit in SARS-CoV-2 with remdesivir, the combination of lopinavir/ritonavir (LPV/r) plus ribavirin; and strong evidence for LPV/r plus ribavirin against Middle East Respiratory Syndrome (MERS) for post-exposure prophylaxis in healthcare workers.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32736197" target="_blank">32736197</a>
</td>
<td style="text-align:center;">
Age, Neutrophil-To-Lymphocyte Ratio (NLR), acute myocardial injury, and levels of C-reactive protein (CRP), lactate dehydrogenase (LDH), and CD3 T cells counts were independently associated with death, while arbidol and ribavirin were protective from death. […] There were 312 (45.8%) patients with cardiovascular disease, of whom 23.4% died. β-blockers, ACEI/ARB, arbidol, and ribavirin might have a beneficial effect for severe COVID-19 patients with cardiovascular disease. […] Clinicians should adopt more aggressive strategies for patients with a high NLR (&gt;6.66) combined with myocardial injury. β-blockers and ACEI/ARB, as well as arbidol and ribavirin, were effective in COVID-19 patients with cardiovascular disease.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32754388" target="_blank">32754388</a>
</td>
<td style="text-align:center;">
In this article, we have compiled comprehensive data on many candidate drugs such as remdesivir, favipiravir, ribavirin, umifenovir, arbidol, lopinavir, ritonavir, baricitinib, hydroxychloroquine, nitazoxanide, azithromycin, baloxavir, oseltamivir, losartan, and tocilizumab.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32758569" target="_blank">32758569</a>
</td>
<td style="text-align:center;">
The docking was done with most discussed drugs for SARS-CoV-2 like Ritonavir, Lopinavir, Remdesivir, Chloroquine, Hydroxychloroquine (HCQ), routine antiviral drugs like Oseltamivir and Ribavirin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32765274" target="_blank">32765274</a>
</td>
<td style="text-align:center;">
Eligible patients with mild to moderate COVID-19 were randomized into three groups: ribavirin (RBV) plus interferon-α (IFN-α), lopinavir/ritonavir (LPV/r) plus IFN-α, and RBV plus LPV/r plus IFN-α at a 1:1:1 ratio.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32767929" target="_blank">32767929</a>
</td>
<td style="text-align:center;">
Compared with control compounds (ribavirin, arbidol), the docking score of quercetin to the IL-6 receptor was highest, with a score of 5. […] Furthermore, the scores of three key components to SARS-CoV-2 are large as 4, 5, and 5, respectively, which are even better than those of ribavirin at 3.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32768505" target="_blank">32768505</a>
</td>
<td style="text-align:center;">
These include anti-viral agents (remdesivir, ribavirin, lopinavir-ritonavir, favipiravir, chloroquine, hydroxychloroquine, oseltamivir, umifenovir), immunomodulatory agents (tocilizumab, interferons, plasma transfusions), and adjunctive agents (azithromycin, corticosteroids), among other miscellaneous agents.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32777318" target="_blank">32777318</a>
</td>
<td style="text-align:center;">
The skin reactions of antimalarials (chloroquine and hydroxychloroquine), antivirals (lopinavir/ritonavir, ribavirin with or without interferon, oseltamivir, remdesivir, favipiravir, and darunavir), and treatments for complications (imatinib, tocilizumab, anakinra, immunoglobulins, corticosteroids, colchicine and low molecular weight heparins) are analyzed.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32786685" target="_blank">32786685</a>
</td>
<td style="text-align:center;">
The drug repurposing study revealed the high potential of noscapine and proximal binding to the Mpro enzyme in a comparative binding pattern analyzed with chloroquine, ribavirin, and favipiravir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32787752" target="_blank">32787752</a>
</td>
<td style="text-align:center;">
Furthermore, ribavirin may also be a potential treatment against CHIKV; sofosbuvir against ZIKV; celgosivir against DENV, and favipiravir against EBOV and MARV, representing new hopes against these pathogens.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32807688" target="_blank">32807688</a>
</td>
<td style="text-align:center;">
Lopinavir-interferon α2b boosted ribavirin following with lopinavir boosted budesonide might be a potent treatment for viral clearance.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32812025" target="_blank">32812025</a>
</td>
<td style="text-align:center;">
We assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19. […] Patients were randomly assigned to 400 mg sofosbuvir, 60 mg daclatasvir and 1200 mg ribavirin (intervention group) or to standard care (control group). […] The number of ICU admissions in the sofosbuvir/daclatasvir/ribavirin group was not significantly lower than the control group (0 versus 4, P = 0.109). […] The cumulative incidence of recovery was higher in the sofosbuvir/daclatasvir/ribavirin arm (Gray’s P = 0.033). […] There were trends in favour of the sofosbuvir/daclatasvir/ribavirin arm for recovery and lower death rates.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32812051" target="_blank">32812051</a>
</td>
<td style="text-align:center;">
Subjects were divided into two arms with one arm receiving ribavirin and the other receiving sofosbuvir/daclatasvir. […] Sixty-two subjects met the inclusion criteria, with 35 enrolled in the sofosbuvir/daclatasvir arm and 27 in the ribavirin arm. […] The median duration of stay was 5 days for the sofosbuvir/daclatasvir group and 9 days for the ribavirin group. […] The mortality in the sofosbuvir/daclatasvir group was 2/35 (6%) and 9/27 (33%) for the ribavirin group.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32827400" target="_blank">32827400</a>
</td>
<td style="text-align:center;">
Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32834942" target="_blank">32834942</a>
</td>
<td style="text-align:center;">
A number of antiviral drugs such as Ribavirin, Remdesivir, Lopinavir/ritonavir, Azithromycin and Doxycycline have been recommended or are being used to treat COVID-19 patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32848446" target="_blank">32848446</a>
</td>
<td style="text-align:center;">
Antiviral medication (lopinavir, darunavir, favipiravir, remdesivir, ribavirin, oseltamivir, tocilizumab, and umifenovir), ACE inhibitors, interferon-α2b, co-therapy with azithromycin, inhaling iNO, and oxygen therapy can be used for treatment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32849934" target="_blank">32849934</a>
</td>
<td style="text-align:center;">
Lopinavir/ritonavir was found beneficial when administered with interferon and ribavirin, but one clinical trial on its sole use proved contrary.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32864162" target="_blank">32864162</a>
</td>
<td style="text-align:center;">
In this review, we summarized the pharmacogenomic literature available for COVID-19 drug therapies including hydroxychloroquine, chloroquine, azithromycin, remdesivir, favipiravir, ribavirin, lopinavir/ritonavir, darunavir/cobicistat, interferon beta-1b, tocilizumab, ruxolitinib, baricitinib, and corticosteroids. […] We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). […] We also identified other variants, that are associated with adverse effects, most notable in hydroxychloroquine/chloroquine (G6PD; hemolysis), ribavirin (ITPA; hemolysis), and interferon β -1b (IRF6; liver toxicity).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32869558" target="_blank">32869558</a>
</td>
<td style="text-align:center;">
In general, the combination of antibiotics, ribavirin, and corticosteroids was considered as a standard treatment for patients with SARS. […] For patients with MERS, ribavirin, lopinavir/ritonavir, interferon, and convalescent plasma were continuously recommended. […] There was limited evidence for the effect of corticosteroids, other antiviral drugs like ribavirin, and favipiravir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32878881" target="_blank">32878881</a>
</td>
<td style="text-align:center;">
In silico screening, molecular mechanics and molecular dynamics simulation (MDS) analysis suggest ribavirin, ascorbate, lopinavir and hydroxychloroquine have strong interaction at the RBD-hACE2 interface.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32879113" target="_blank">32879113</a>
</td>
<td style="text-align:center;">
Hot anti-SARS-CoV-2 drugs include interferon α, ribavirin, lopinavir/ritonavir, chloroquine phosphate, abidol, as well as hydroxychloroquine sulfate and remdesivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32884821" target="_blank">32884821</a>
</td>
<td style="text-align:center;">
There is no vaccine for COVID-19, so antiviral drugs (interferon alfa, ribavirin) may be useful to prevent COVID-19; however, severe control measures implemented in China have significantly mitigated the spread of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32887660" target="_blank">32887660</a>
</td>
<td style="text-align:center;">
The most common treatment options used were hydroxychloroquine (79.7%), ribavirin (65.2%), and oxygen therapy (78.8%).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32889701" target="_blank">32889701</a>
</td>
<td style="text-align:center;">
Number of drugs such as remdesivir, favipiravir, ribavirin, lopinavir, ritonavir, darunavir, arbidol, chloroquine, hydroxychloroquine, tocilizumab and interferons have shown inhibitory effects against the SARS-CoV2 in-vitro as well as in clinical conditions.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32894567" target="_blank">32894567</a>
</td>
<td style="text-align:center;">
Two retrospective matched-cohort studies reported the use of lopinavir/ritonavir in combination with ribavirin for SARS patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32910955" target="_blank">32910955</a>
</td>
<td style="text-align:center;">
Evaluation of antiviral activity using cell-based assay showed that NSC629301 and NSC71097 could strongly inhibit the cytopathic effect and also reduced replication of FIPV in CRFK cells in all examined conditions with the low range of EC50 (6.11 ± 1.90 to 7.75 ± 0.48 μM and 1.99 ± 0.30 to 4.03 ± 0.60 μM, respectively), less than those of ribavirin and lopinavir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32949079" target="_blank">32949079</a>
</td>
<td style="text-align:center;">
During the post-transplant period, in profound leukopenia (below 10 leukocytes/µL), she was diagnosed with SARS-CoV-2, MPV, and RSV pneumonia and was treated with ribavirin and chloroquine.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32957417" target="_blank">32957417</a>
</td>
<td style="text-align:center;">
Ribavirin has activity against extensive RNA and DNA viruses. […] We plan to systematically review the use of ribavirin in patients with coronavirus-related pneumonia and meta-analyze the data with updated studies. […] Ribavirin of any dose or route will be compared with the control group of other medication, placebo, or no medication. […] The efficacy and safety of ribavirin for treatment of coronavirus-related pneumonia will be systematically reviewed and summarized. […] The forthcoming results of the ongoing studies focusing on ribavirin in patients with the 2019 noel coronavirus disease will also be included.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32965013" target="_blank">32965013</a>
</td>
<td style="text-align:center;">
There are several potential medications available for COVID-19, such as Interferon α (IFN-α), Teicoplanin, Ribavirin, Galidesivir, Lopinavir/Ritonavir, Chloroquine phosphate, Arbidol, Velpatasvir, Favipiravir, Ledipasvir, Remdesivir, Sofosbuvir, Darunavir, Qingfei Paidu Decoction (QPD), and Imatinib.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/32989996" target="_blank">32989996</a>
</td>
<td style="text-align:center;">
Many patients however receive off-label antivirals such as lopinavir/ritonavir, ribavirin and/or chloroquine and /or interferons. […] Keywords: COVID-19, coronavirus, distress syndrome, lopinavir/ritonavir, ribavirin, chloroquine, interferons.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33029193" target="_blank">33029193</a>
</td>
<td style="text-align:center;">
We aimed to analyze and evaluate the safety signals of ribavirin-interferon combination through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS), so as to provide reference for the rationale use of these agents in the management of relevant toxicities emerging in patients with novel coronavirus pneumonia (COVID-19). […] The ADE (adverse drug event) signal detection based on FAERS is helpful to clarify the potential adverse events related to ribavirin-interferon combination for novel coronavirus therapy; clinicians should pay attention to the adverse reactions of gastrointestinal and blood systems, closely monitor the fluctuations of the platelet count, and carry out necessary mental health interventions to avoid serious adverse events.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33029696" target="_blank">33029696</a>
</td>
<td style="text-align:center;">
The repurposed drugs like Chloroquine and Hydroxychloroquine, Tenofovir, Remdesivir, Ribavirin, Darunavir, Oseltamivir, Arbidol (Umifenovir), Favipiravir, Anakinra, and Baricitinib are already being used in clinical trials to treat the COVID-19 patients.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33031797" target="_blank">33031797</a>
</td>
<td style="text-align:center;">
So far, chloroquine, lopinavir, hydroxychloroquine, azithromycin, favipiravir, ribavirin, darunavir, remdesivir, and umifenovir have been tested in COVID-19 clinical trials.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33041111" target="_blank">33041111</a>
</td>
<td style="text-align:center;">
According to level 1 evidence reviewed here, the most effective SARS-Co-V-2 pharmacologic treatments include remdesivir for mild to severe disease, and a triple regimen therapy consisting of lopinavir-ritonavir, ribavirin and interferon beta-1b for mild to moderate disease.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33049737" target="_blank">33049737</a>
</td>
<td style="text-align:center;">
Chloroquine, remdesivir, favipiravi, lopinavir, ribavirin or ritonavir have shown efficacy to inhibit coronavirus in vitro.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33080900" target="_blank">33080900</a>
</td>
<td style="text-align:center;">
Our MD simulations suggest that the combination of caffeine with ribavirin shows a stronger interaction with 6VW1, while in case of favipiravir+nicotine, 6LZG shows potent efficacy of these interaction, proposing the potent efficacy of these combinations for blocking ACE2 receptor against SARS-CoV-2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33081849" target="_blank">33081849</a>
</td>
<td style="text-align:center;">
To compare the safety and efficacy of Hydroxychloroquine with Ribavirin and standard treatment in patients with non-severe COVID-19 infection 2. […] To compare the safety and efficacy of standard treatment, Lopinavir-ritonavir with Ribavarin, and Hydroxychloroquine with Ribavirin in patients with severe COVID-19 infection TRIAL DESIGN: The study is an Open label, Parallel arm design, stratified randomised controlled trial.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33102687" target="_blank">33102687</a>
</td>
<td style="text-align:center;">
The results indicate promising effects of such compounds to be used in further experimental and clinical trials; Chloroquine, Chloroquine-OH, and Umifenovir as viral entry inhibitors, Remdesivir, Ribavirin, Lopinavir, Ritonavir, and Darunavir as viral replication inhibitors, and Sirolimus are the examples, which were tested clinically on patients after comprehensive assessments of the available data on molecular simulation.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33107812" target="_blank">33107812</a>
</td>
<td style="text-align:center;">
Docking and simulation results indicated that epicatechin, embelin, hesperidin, cafestol, murrayanine and murrayaquinone-A have higher inhibition efficacy over at least one of the known antiviral drugs such as Hydroxychloroquine, Remdesivir and Ribavirin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33116663" target="_blank">33116663</a>
</td>
<td style="text-align:center;">
All patients received antiviral treatment (arbidol, oseltamivir, and ribavirin); 78.4% of patients received antibiotic therapy (moxifloxacin, levofloxacin, and cefdinir); patients in the moderate disease group received more antibiotic therapy than those in the mild disease group.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33120785" target="_blank">33120785</a>
</td>
<td style="text-align:center;">
Intravenous immunoglobulin, oseltamivir, and ribavirin were associated with reduced mortality in normal weight patients.Overweight is a worldwide health problem.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33128482" target="_blank">33128482</a>
</td>
<td style="text-align:center;">
Presently, several drugs, such as hydroxychloroquine, ribavirin, favipiravir (FVP), lopinavir/ritonavir (LPV/r), remdesivir and oseltamivir, have been suggested as effective treatments for SARS-CoV-2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33137863" target="_blank">33137863</a>
</td>
<td style="text-align:center;">
At present, drugs, including lopinavir/ritonavir, chloroquine phosphate, abidol, IFN-α atomization and ribavirin, are commonly used in clinical practice.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33156564" target="_blank">33156564</a>
</td>
<td style="text-align:center;">
The list of drugs used for COVID-19 treatment includes a combination of lopinavir and ritonavir, remdesivir, favipiravir, alpha-interferon, ribavirin, atazanavir, umifenovir, and tocilizumab.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33183004" target="_blank">33183004</a>
</td>
<td style="text-align:center;">
Currently, there are no FDA-licensed drugs to treat arenavirus infection except for the off-labeled use of ribavirin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33190802" target="_blank">33190802</a>
</td>
<td style="text-align:center;">
With the development of this pandemic, the number of clinical studies on antiviral therapy, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir, ribavirin, arbidol, interferon, favipiravir, oseltamivir, nitazoxanide, nelfinavir, and camostat mesylate, has been increasing.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33191206" target="_blank">33191206</a>
</td>
<td style="text-align:center;">
These drugs include fingolimod, colchicine, N4-hydroxycytidine, remdesivir, methylprednisone, oseltamivir, icatibant, perphanizine, viracept, emetine, homoharringtonine, aloxistatin, ribavirin, valrubicin, famotidine, almitrine, amprenavir, hesperidin, biorobin, cromolyn sodium, and antibodies- tocilzumab and sarilumab.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33191908" target="_blank">33191908</a>
</td>
<td style="text-align:center;">
Interferon-α (IFN-α), lopinavir/ritonavir, chloroquine phosphate, arbidol, ribavirin, remdesivir, and dexamethasone are the therapeutic drugs recommended for treating 2019-nCoV disease (COVID-19 disease).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33193695" target="_blank">33193695</a>
</td>
<td style="text-align:center;">
Ribavirin was predicted to be the best small molecular drug, with a higher molecular binding energy of -6.39 kcal/mol with human angiotensin-converting enzyme 2 (ACE2), followed by remdesivir (-7.4 kcal/mol), mycophenolic acid (-5.35 kcal/mol), and chloroquine (-6.29 kcal/mol). […] Ribavirin, remdesivir, and chloroquine have been under clinical trials or supported by recent works.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33199136" target="_blank">33199136</a>
</td>
<td style="text-align:center;">
The article mainly focused on the development and possible application of various FDA approved drugs, including chloroquine, remdesivir, favipiravir, nefamostate mesylate, penciclovir, nitazoxanide, ribavirin etc., vaccines under development and various registered clinical trials exploring different therapeutic measures for the treatment of COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33218161" target="_blank">33218161</a>
</td>
<td style="text-align:center;">
Lopinavir/ritonavir, hydroxychloroquine, antibiotics, ribavirin, oseltamivir, and interferon were administered to 35.8%, 28.4%, 38.1%, 0.1%, 0.3%, and 0.9% of patients, respectively.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33219182" target="_blank">33219182</a>
</td>
<td style="text-align:center;">
Oseltamivir, Ribavirin in patients with COVID-19; but none of which showed efficacy of antiviral therapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33240733" target="_blank">33240733</a>
</td>
<td style="text-align:center;">
The rash started after he took azithromycin, oseltamivir, ribavirin, lopinavir, hydroxychloroquine, prednisolone, ceftriaxone, clindamycin, interferon (IFN) beta, and ceftazidime for COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33257051" target="_blank">33257051</a>
</td>
<td style="text-align:center;">
Chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, oseltamivir, remdesivir, favipiravir, and umifenovir represent the major repurposed drugs used as potential experimental agents for COVID-19 whereas azithromycin, dexamethasone, tocilizumab, sarilumab, famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33261845" target="_blank">33261845</a>
</td>
<td style="text-align:center;">
Studies included repurposed drugs mainly against non-structural proteins of SARS-CoV2: the main 3C-like protease (Lopinavir, Ritonavir, Indinavir, Atazanavir, Nelfinavir, and Clocortolone), RNA-dependent RNA polymerase (Remdesivir and Ribavirin), and the papain-like protease (Mycophenolic acid, Telaprevir, Boceprevir, Grazoprevir, Darunavir, Chloroquine, and Formoterol). […] The review revealed the best-documented multi-target drugs repurposed by computational methods for COVID-19 therapy as follows: antiviral drugs commonly used to treat AIDS/HIV (Atazanavir, Efavirenz, and Dolutegravir Ritonavir, Raltegravir, and Darunavir, Lopinavir, Saquinavir, Nelfinavir, and Indinavir), HCV (Grazoprevir, Lomibuvir, Asunaprevir, Ribavirin, and Simeprevir), HBV (Entecavir), HSV (Penciclovir), CMV (Ganciclovir), and Ebola (Remdesivir), anticoagulant drug (Dabigatran), and an antifungal drug (Itraconazole).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33276811" target="_blank">33276811</a>
</td>
<td style="text-align:center;">
In the first stage, three subjects are given ixekizumab (“Taltz”) (80 mg/ml, 160 mg as a single hypodermic injection) and antiviral therapy (α-interferon (administer 5 million U by aerosol inhalation twice daily), lopinavir/ritonavir (administer 100mg by mouth twice daily, for the course of therapy no more than 10 days), chloroquine (administer 500mg by mouth twice daily, for the course of therapy no more than 10 days), ribavirin (administer 500mg by intravenous injection two to three times a day, for the course of therapy no more than 10 days), or arbidol (administer 200mg by mouth three times a day, for the course of therapy no more than 10 days), but not more than 3 types).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33283765" target="_blank">33283765</a>
</td>
<td style="text-align:center;">
Therapeutic treatment has similarity in using ribavirin and extracorporeal membrane oxygenation but lack of efficacious treatment in both cases of SARAS CoV2 and Hantaan virus.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33290476" target="_blank">33290476</a>
</td>
<td style="text-align:center;">
Similarly, Galidesivir, Favipiravir, Ribavirin, N4-hydroxycytidine (EIDD-1931), and EIDD-2801 (a prodrug of EIDD-1931) were also found to be effective against COVID-19. […] However, although Favipiravir and Ribavirin can make stable base pair interactions by using their keto and enol tautomers, the formation of the latter pairs would be less probable due to the endothermic nature of the products. […] Interestingly, the insertions of all of the RNA bases are found to be possible against the keto tautomer of Favipiravir, while the keto tautomer of Ribavirin has a clear preference for G.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33297724" target="_blank">33297724</a>
</td>
<td style="text-align:center;">
nucleotide synthesis inhibitors are presented that ultimately interfere with viral nucleic acid synthesis, with ribavirin being the most prominent and widely used example.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33309661" target="_blank">33309661</a>
</td>
<td style="text-align:center;">
Hence, ritonavir may potentiate the therapeutic properties of drugs such as remdesivir, favipiravir and ribavirin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33312897" target="_blank">33312897</a>
</td>
<td style="text-align:center;">
Treatments used for COVID-19 therapy; azithromycin, atazanavir, lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, nitazoxanide, ribavirin, and tocilizumab, interact with immunosuppressive treatments, most importantly with calcineurin inhibitors.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33313272" target="_blank">33313272</a>
</td>
<td style="text-align:center;">
Randomised controlled trials (RCTs) and controlled cohort studies reporting antiviral therapies, including ribavirin, remdesivir, lopinavir/ritonavir, arbidol, chloroquine, hydroxychloroquine, and interferon, for SARS, MERS, and COVID-19 will be included.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33334287" target="_blank">33334287</a>
</td>
<td style="text-align:center;">
The development of vaccine or medicines for the same are under progress and this short review will summarize the most potential candidates such as Remdesivir, Lopinavir and Ritonavir, Chloroquine, Hydroxychloroquine, Hydroxychloroquine with Azithromycin, Favipiravir, Umifenovir, and Ribavirin for its medicinal treatment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33336316" target="_blank">33336316</a>
</td>
<td style="text-align:center;">
Remdesivir, dexamethasone, azithromycin, favipiravir, lopinavir/ritonavir, atazanavir, hydroxychloroquine, interferon beta, ribavirin, tocilizumab, anakinra and sarilumab were identified as experimental drugs being used in COVID-19 trials as of November 2020.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33347311" target="_blank">33347311</a>
</td>
<td style="text-align:center;">
The inhibitors of the virus entry to cells and RdRp, such as Arbidol, remdesivir, favipiravir, EIDD-2081, and ribavirin, are in clinical trials, while most of the protease inhibitors are mainly calculated by molecular docking technology, which needs in vivo and in vitro experiments to prove the effect for SARS-CoV-2.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33364959" target="_blank">33364959</a>
</td>
<td style="text-align:center;">
Triple therapy of ribavirin, lopinavir, and interferon β-1b showed early viral negative conversion, and the major effect may be related to interferon.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33376954" target="_blank">33376954</a>
</td>
<td style="text-align:center;">
In this article, we reviewed almost all the RCT reports on monotherapies and combined therapies with antiviral agents for COVID-19, and found that among the reports on monotherapies, only remdesivir, and among combined antiviral agents, only the combined regimen with interferon-β1b, lopinavir-ritonavir and ribavirin were effective and safe based on evidences from RCTs.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33412996" target="_blank">33412996</a>
</td>
<td style="text-align:center;">
Abigail (80.9%), ribavirin (36.6%), oseltamivir (38.9%), interferon (16.4%), and ganciclovir (14.5%) were used for the anti-viral treatment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33421347" target="_blank">33421347</a>
</td>
<td style="text-align:center;">
DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID-19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT-prolongation, retinopathy, increased risk of infection, and hepatotoxicity.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33421473" target="_blank">33421473</a>
</td>
<td style="text-align:center;">
In-silico screening, molecular mechanics, molecular dynamics simulation (MDS) analysis suggest ribavirin, and remdesivir have good interaction with the binding site of the RdRp protein as compared to other antiviral investigated. […] Hence, ribavirin and remdesivir were used for the denovo fragments based antiviral design.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33491234" target="_blank">33491234</a>
</td>
<td style="text-align:center;">
Six proposed COVID-19 therapeutics were identified as possessing ototoxic side effects including chloroquine and hydroxychloroquine, azithromycin, lopinavir-ritonavir, interferon, ribavirin, and ivermectin.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33492492" target="_blank">33492492</a>
</td>
<td style="text-align:center;">
The pressure to produce drugs and vaccines against the ongoing pandemic has resulted in the use of some drugs such as azithromycin, chloroquine (sulfate and phosphate), hydroxychloroquine, dexamethasone, favipiravir, remdesivir, ribavirin, ivermectin, and lopinavir/ritonavir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33505872" target="_blank">33505872</a>
</td>
<td style="text-align:center;">
The nucleotide inhibitors such as sofosbuvir, ribavirin, galidesivir, remdesivir, favipiravir, cefuroxime, tenofovir, and hydroxychloroquine (HCHL), setrobuvir, YAK, and IDX-184 were found to be effective in binding to SARS-CoV-2 RNA-dependent RNA polymerase.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33515771" target="_blank">33515771</a>
</td>
<td style="text-align:center;">
To assess the efficacy and safety of ribavirin and interferon-α (RBV/IFN-α) therapy in patients with COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33523551" target="_blank">33523551</a>
</td>
<td style="text-align:center;">
The patient was treated with tocilizumab, and a combination of lopinavir/ritonavir, ribavirin, interferon-β1b.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33527086" target="_blank">33527086</a>
</td>
<td style="text-align:center;">
In this study, we examine at the molecular level the interaction of this drug and that of similar nucleotide analogue inhibitors, ribavirin and favilavir, by relying on atomistic molecular simulations and advanced sampling. […] Surprisingly, however, ribavirin and favilavir do not bind the nucleotide on the complementary strand as effectively and seem to act by a different mechanism than remdesivir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33533219" target="_blank">33533219</a>
</td>
<td style="text-align:center;">
The review discusses the main representatives of these groups of drugs - ribavirin, riamilovir, umifenovir, favipiravir.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33541491" target="_blank">33541491</a>
</td>
<td style="text-align:center;">
The unconventional antiviral group was given α-interferon combined with LPV/R and Abidor or Ribavirin or Chloroquine.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33546185" target="_blank">33546185</a>
</td>
<td style="text-align:center;">
TG’s antiviral performance was significantly better than remdesivir and ribavirin in their respective inhibition of OC43 and RSV.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33550050" target="_blank">33550050</a>
</td>
<td style="text-align:center;">
In addition, it refers to drugs such as Chloroquine/Hydroxychloroquine, Lopinavir/Ritonavir, darunavir, ribavirin, remdesivir, and favipiravir, which have undergone clinical trials for coronavirus disease 2019 (COVID-19) treatment.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33555378" target="_blank">33555378</a>
</td>
<td style="text-align:center;">
Remdesivir, Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33563148" target="_blank">33563148</a>
</td>
<td style="text-align:center;">
To date, two known nucleoside drugs (Ribavirin, Favipiravir) have been recommended for the treatment of SARS-CoV-2 infection and nine hit compounds based on nucleosides and their analogues have been found, one of which efficiently suppressing SARS-CoV-2 replication and eight others inhibiting SARS-CoV replication.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33565392" target="_blank">33565392</a>
</td>
<td style="text-align:center;">
The main progress in international critical care medicine in 2020 are: the reflections on the mandatory of implementation of the 1-hour cluster treatment strategy for sepsis are still continuing; the “metabolic resuscitation” therapy, represented by large dose of vitamin C, failed to yield positive results; the global epidemic of coronavirus disease 2019 (COVID-19) continues to spread, with evidences indicating Dexamethasone, Remdesivir or interferon β-1b (IFNβ-1b), Lopinavir/Ritonavir and ribavirin as promising therapy; conservative oxygen therapy did not exert positive effects neither for mechanical ventilated patients nor for acute respiratory distress syndrome (ARDS) patient; the concept of lung- and diaphragm-protective mechanical ventilation illuminates a new opportunity to potentially improve clinical outcomes for critically ill patients; there was no positive evidence for stress ulcer prophylaxis and timing of endoscopy for severe acute upper gastrointestinal bleeding; early initiation of renal-replacement therapy (RRT) for critically ill patients with acute kidney injury (AKI) has not shown positive effect.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33574271" target="_blank">33574271</a>
</td>
<td style="text-align:center;">
We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). […] We also identified other variants, that are associated with adverse effects, most notable in hydroxychloroquine/chloroquine (G6PD; hemolysis), ribavirin (ITPA; hemolysis), and interferon β -1b (IRF6; liver toxicity).
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33590901" target="_blank">33590901</a>
</td>
<td style="text-align:center;">
This trial compared the rate and time of viral clearance in subjects receiving the combination of nitazoxanide, ribavirin and ivermectin plus Zinc vs. those receiving supportive treatment. […] This trial concluded that combined use of Nitazoxanide, Ribavirin, and Ivermectin plus zinc supplement effectively clear the SARS-COV2 from nasopharynx in shorter time than the symptomatic therapy.
</td>
</tr>
<tr>
<td style="text-align:center;">
<a href="https://pubmed.ncbi.nlm.nih.gov/33593415" target="_blank">33593415</a>
</td>
<td style="text-align:center;">
No statistical differences were found in the duration of positive PCR results from pharyngeal swabs in 25 children with COVID-19 who received antiviral drugs (lopinavir-ritonavir, ribavirin, and arbidol) as compared with duration in 39 children without antiviral therapy [median 10 vs. 9 d, P = 0.885]. […] Lopinavir-ritonavir, ribavirin and arbidol do not shorten the duration of positive PCR results from pharyngeal swabs in children with COVID-19.
</td>
</tr>
</tbody>
</table>
</div>

    </div>

    





















  </div>
</article>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js" integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js" integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    <script>const isSiteThemeDark = false;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://procovid19.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/academic.min.4aaf2d64e50f8e54cf66dcc54147a22e.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  
  <p class="powered-by">
    
      
      <a href="/supp/faq/">FAQ</a>
    
  </p>
  

  <p class="powered-by">
    BioHub - UFPE &middot; 

    Powered by the
    <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
    <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
